Clinical Trial Search

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants

Primary: Participants Enrolled — 36 Participants

Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg

Primary: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination — 10; 12; 10; 2 Participants

Primary: Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29 — 0; 3; 0; 0 Participants

Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants

Primary: Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 32; 36; 37; 43 Participants

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: Positive Percent Agreement — 52 percent of nasal swabs

Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: Number of Participants With COVID-19 Antibodies — 8; 284 Participants — p=>0.18

Primary: Number of Participants Reporting Solicited Local or Systemic Adverse Events (AEs) — 3; 4; 3; 5 Participants

Primary: Grade 2 and Higher Adverse Events 4 Weeks After Administration. — 0; 0; 0; 0 Participants

Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events

Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants

Primary: Positive Percent Agreement — 53; 2 Participants

Primary: Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 in Seronegative Participants With Onset at…

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose — 744; 55 Participants — p=<.0001

Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants

Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants

Primary: Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay — 120.5; 104.3; 137.7; 97.3 titer

Primary: Number of Serious Adverse Events — 0; 0; 0; 0 serious adverse events

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: 30 Candidate Ag Test Self-collections — 53; 0 Participants

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…